Kong Xiangyue, Li Fengjuan, Wang Yuan
Beijing Collaborative Innovation Centre for Cardiovascular Disorders, the Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China.
J Cell Mol Med. 2025 Mar;29(5):e70453. doi: 10.1111/jcmm.70453.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Over the past decade, studies have demonstrated that circulating long non-coding RNAs (lncRNAs)-recognised for their stability and ease of detection-serve as crucial regulators and potential biomarkers in multiple diseases. LncRNAs regulate key processes, including endothelial function, vascular remodelling, and myocardial hypertrophy, all of which influence CVD progression. Additionally, lncRNAs display cell-, tissue-, and disease-specific expression patterns, making them ideal therapeutic targets or tools. This review presents a comprehensive overview of the current understanding of lncRNAs in CVDs, examining their mechanisms of action and recent research advances. It also addresses the use of lncRNAs as diagnostic and prognostic markers, as well as potential applications of RNA therapeutics in novel treatment strategies.
心血管疾病（CVDs）是全球发病和死亡的主要原因。在过去十年中，研究表明，循环长链非编码RNA（lncRNAs）因其稳定性和易于检测而被认可，在多种疾病中作为关键调节因子和潜在生物标志物发挥作用。LncRNAs调节关键过程，包括内皮功能、血管重塑和心肌肥大，所有这些都会影响CVD的进展。此外，lncRNAs表现出细胞、组织和疾病特异性的表达模式，使其成为理想的治疗靶点或工具。本综述全面概述了目前对CVDs中lncRNAs的理解，研究了它们的作用机制和最新研究进展。它还讨论了lncRNAs作为诊断和预后标志物的用途，以及RNA疗法在新型治疗策略中的潜在应用。
